Showing results (141-150 of 223) with videos related to
Sort By:
Pageof 23
Bioorganic & Medicinal Chemistry|March 5, 2003
Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enesDaniele Passarella, Raffaele Favia, Alessandra Giardini, et al.Annals of Neurology|April 1, 1997
Immunochemical analysis of dopamine transporter protein in Parkinson's diseaseG W Miller, J K Staley, C J Heilman, et al.Psychopharmacology|August 4, 2004
Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 5' nuclease assayGuanshan Zhu, Robert H Lipsky, Ke Xu, et al.Acta Neurologica Scandinavica|March 4, 2009
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's diseaseJ Pablo, S A Banack, P A Cox, et al.Experimental Neurology|April 8, 1999
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's diseaseG W Miller, J D Erickson, J T Perez, et al.Neuroscience Letters|January 6, 2007
Phenotypic associations of tau and ApoE in Parkinson's diseaseSpiridon Papapetropoulos, Matthew J Farrer, Jeremy T Stone, et al.European Journal of Human Genetics : EJHG|August 12, 2010
Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphismsRyan M Smith, Houda Alachkar, Audrey C Papp, et al.Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.Journal of Neurochemistry|June 22, 2013
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's diseaseDavid S Goldstein, Patti Sullivan, Courtney Holmes, et al.Plos One|September 28, 2013
Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseasesValeriy Duka, Jae-Hoon Lee, Joel Credle, et al.Pageof 23